Drug Trial Radar · NCT00074984
A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease
Last checked: Nov 20, 2026Latest source record: Dec 27, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Feb 2001
Primary completion
Jan 2004
Study completion Jan 2004
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 25, 2003
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the a-galactosidase A enzyme. Fabrazyme (agalsidase beta) is a drug that helps to breakdown and remove certain types of fatty substances called "glycolipids." These glycolipids are normally present within the body in most cells. In Fabry disease, glycolipids build up in various tissues such as the liver, kidney, skin, and blood vessels because a-galactosidase A is not present, or is present in small quantities. The build up of glycolipid ("globotriaosylceramide" or "GL-3") levels in these tissues in particular is thought to cause the clinical symptoms that are common to Fabry disease. This study will test the safety and efficacy of Fabrazyme in the treatment of patients with Fabry disease.
Conditions
- Fabry Disease
Interventions
Fabrazyme (agalsidase beta)Biological
1mg/kg Fabrazyme (agalsidase beta) every 2 weeks
PlaceboBiological
1 mg/kg placebo intravenously every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing a Clinically Significant Renal, Cardiac or Cerebrovascular Event and/or Death in Fabrazyme (Agalsidase Beta) Patients as Compared to Placebo PatientsTime frame: up to 35 months
Locations
26 sites in 6 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Cedars-Sinai Medical Center
Los Angeles, California
University of San Francisco
San Francisco, California
University of Connecticut Health Partners
Farmington, Connecticut
Oncology Hematology Association
Coral Springs, Florida
Emory University School of Medicine
Atlanta, Georgia
Children's Memorial Hospital
Chicago, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Massachusetts General Hospital
Boston, Massachusetts
Gene Therapy Center - Dept. of Pediatrics and Institute of Human Genetics
Minneapolis, Minnesota
Children's Hospital
Buffalo, New York
Mount Sinai School of Medicine
New York, New York
University of Rochester School of Medicine
Rochester, New York
Duke University Medical Center
Durham, North Carolina
Children's Hospital Medical Center
Cincinnati, Ohio
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania
Baylor College of Medicine
Houston, Texas
University of Washington School of Medicine
Seattle, Washington
Queen Elizabeth II Health Center
Halifax, Nova Scotia, Canada
North York General Hospital
Toronto, Ontario, Canada
Hopital du Sacre-Coeur de Montreal
Montreal, Quebec, Canada
University Hospital
Prague, Czechia
Sopron Megyei Jogu Varos Erzsebet Korhaz
Sopron, Hungary
Klinika Chorob Metabolicznych Instytut
Warsaw, Poland
Hope Hospital
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.